Press Digest: Financial Times - Sept 1

SK Bioscience Co

01/09/2021 01:18

Sept 1 (Reuters) - The following are the top stories in the
Financial Times. Reuters has not verified these stories and does
not vouch for their accuracy.
    
    Headlines
    - Activist calls for Canadian National CEO to resign after
rail deal hits hurdle https://on.ft.com/3gPlEoX
    
    - GSK hopes for vaccine success as new shot enters
late-stage trial https://on.ft.com/3mOqK8J
    
    - Ryanair predicts return to pre-pandemic passenger numbers
this winter https://on.ft.com/3DCQlr2
    
    - North Sea oil producers push UK to back 18 new projects https://on.ft.com/3Brhcog
    
    Overview
    - Chris Hohn, head of UK hedge fund TCI Management Ltd, has
called for Canadian National Railway Co  CNR.TO  to cancel its
deal with Kansas City Southern  KSU.N  and also demanded that
CN's Chief Executive Jean-Jacques Ruest and chair Robert Pace
resign.
    
    - A third COVID-19 shot produced by South Korea's SK
Bioscience  302440.KS  using GlaxoSmithKline Plc's  GSK.L  
adjuvant technology has begun a late-stage clinical trial. 
    
    -  Ryanair Holdings Plc  RYA.I  said that it expects to
return to pre-pandemic levels this winter, banking on a "very
strong recovery" in travel.
    
    - The Oil and Gas UK (OGUK) industry body has called on the
government to back up about 18 new fossil fuel projects, while
the UK has committed to reduce its greenhouse gas emissions to
net zero by 2050.
    

 (Compiled by Bengaluru newsroom)
 ((globalnewsmonitoring@thomsonreuters.com))